Roivant and Priovant Therapeutics have announced a live investor video conference set for June 17, 2025, to discuss brepocitinib, a treatment targeting dermatomyositis (DM) and its potential benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results